Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies.

Cabannes‐Hamy, Aurélie;Peyrade, Frederic;Jardin, Fabrice;Emile, Jean‐François;Van Den Neste, Eric;et.al.
(2018) Cancer Medicine — Vol. 7, n° 3, p. 539-548 (2018)

Files

2018_Cabannes-Hamy_Cancer_Med.pdf
  • Open Access
  • Adobe PDF
  • 150.36 KB

Details

Authors
  • Cabannes‐Hamy, Aurélie
    Author
  • Peyrade, Frederic
    Author
  • Jardin, Fabrice
    Author
  • Emile, Jean‐François
    Author
  • André, MarcUCLouvain
    Author
  • Bosly, AndréUCLouvain
    Collaborator
  • Collaborator
Show more
Abstract
CNS relapse is reported in 2-5% of diffuse large B-cell lymphoma (DLBCL) patients, dramatically decreasing overall survival (OS). Very few studies address incidence and risk factors of CNS relapse in very elderly patients, a challenging population to treat given their commonly associated comorbidities. A retrospective analysis was performed of 270 DLBCL patients >80 years treated between 2004 and 2013 in two multicentre phase II LYSA trials (LNH03-7B, LNH09-7B) evaluating the addition of rituximab or ofatumumab to mini-CHOP as front-line therapy. No patients received CNS prophylaxis. CNS relapse was evaluated according to cumulative incidence, patient characteristics, risk factors, and survival. Median age was 83 years (range: 79-95). After a median follow-up of 28.7 months, eight patients had CNS relapse (3.0%). Median time between inclusion and CNS relapse was 19.2 months (range: 3.2-32.6). Patients survived a median of 1.5 months after CNS relapse (range: 0.4-4.1). Median OS from relapse was significantly lower in CNS relapse patients (1.5 months, 95% CI: 0.4-3.5) compared to patients with non-CNS relapse (6.6 months; 95% CI: 4.6-11.9). No baseline characteristics were associated with CNS relapse. The proportion of patients with CNS disease did not differ significantly between patients with low-intermediate risk according to CNS-IPI and patients with high risk (3% vs. 2.8%, P = 1.00). CNS relapse cumulative incidence in very elderly treatment-naive patients is 1.8% at 2 years and is associated with poor survival. This population had a long median time to CNS relapse. Absence of prophylaxis did not strongly impact CNS relapse incidence.
Affiliations

Citations

Cabannes‐Hamy, A., Peyrade, F., Jardin, F., Emile, J.-F., Delwail, V., Mounier, N., Haioun, C., Perrot, A., Fitoussi, O., Lara, D., Delarue, R., André, M., Offner, F., Ghesquières, H., Pascal, L., Soussain, C., Lazarovici, J., Schiano, J.-M., Gaulard, P., et al. (2018). Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two LYSA studies. Cancer Medicine, 7(3), 539-548. https://doi.org/10.1002/cam4.1139 (Original work published 2018)